DGIdb - RIFAMPIN Drug Record

RIFAMPIN chembl:CHEMBL374478 Approved

Alternate Names:

RIFADIN
RIMACTANE
RIFAMPIN
L-5103
L-5103-LEPETIT
BA-411661E
RIFAMPICIN
NSC-113926
RIFAMYCIN AMP
EREMFAT
NIH-10782
BA-41166E
RFP
3-(((4-METHYL-1-PIPERAZINYL)IMINO)METHYL)RIFAMYCIN SV
chembl:CHEMBL374478
chemidplus:13292-46-1
pubchem.compound:5381226
rxcui:9384
drugbank:01045

Drug Info:

(1 More Sources)

Publications:

Lamba J et al., 2008, Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression., Drug Metab Dispos
Cheng et al., 2009, Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicity., Drug Metab. Dispos.
Chen et al., 2006, Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor., Ann. Clin. Microbiol. Antimicrob.
Suhara Y et al., 2011, Synthesis of novel vitamin K2 analogues with modification at the ω-terminal position and their biological evaluation as potent steroid and xenobiotic receptor (SXR) agonists., J Med Chem
Karthikeyan C et al., 2015, IND-2, a pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinoline derivative, circumvents multi-drug resistance and causes apoptosis in colon cancer cells., Bioorg Med Chem
Kim SH et al., 2012, TNF-α genetic polymorphism -308G/A and antituberculosis drug-induced hepatitis., Liver Int
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Kim SH et al., 2011, NAT2, CYP2C9, CYP2C19, and CYP2E1 genetic polymorphisms in anti-TB drug-induced maculopapular eruption., Eur J Clin Pharmacol
Kwara A et al., 2014, Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance., Pharmacotherapy
Li LM et al., 2012, SLCO1B1 *15 haplotype is associated with rifampin-induced liver injury., Mol Med Rep
Chigutsa E et al., 2011, The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications., Antimicrob Agents Chemother
He YJ et al., 2009, Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism., Clin Chim Acta
Vavricka et al., 2002, Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver., Hepatology
Wang Y et al., 2017, Association of CYP2B6 gene polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a Chinese population., Infect Genet Evol
Cho DY et al., 2016, Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers., Drug Metab Pharmacokinet
Zanger UM et al., 2007, Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance., Pharmacogenomics
Chan SL et al., 2017, Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients., PLoS One
Wu S et al., 2016, Genetic Polymorphisms of Glutathione S-Transferase P1 (GSTP1) and the Incidence of Anti-Tuberculosis Drug-Induced Hepatotoxicity., PLoS One
He L et al., 2015, Involvement of cytochrome P450 1A1 and glutathione S-transferase P1 polymorphisms and promoter hypermethylation in the progression of anti-tuberculosis drug-induced liver injury: a case-control study., PLoS One
Pan H et al., 2019, Association of FAM65B, AGBL4, and CUX2 genetic polymorphisms with susceptibility to antituberculosis drug-induced hepatotoxicity: validation study in a Chinese Han population., Pharmacogenet Genomics
Hennessy EJ et al., 2015, Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity., J Med Chem
Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
Dutreix C et al., 2014, Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin., Eur J Clin Pharmacol
Prueksaritanont et al., 2005, Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes., Pharm. Res.
Wu et al., 1983, Non-competitive inhibition of hepatic and intestinal aryl hydrocarbon hydroxylase activities from rats by rifampin., J. Nat. Prod.
Nanashima K et al., 2012, Genetic variants in antioxidant pathway: risk factors for hepatotoxicity in tuberculosis patients., Tuberculosis (Edinb)

RIFAMPIN RIPOR2

Interaction Score: 6.51

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30720667

Sources:
PharmGKB
RIFAMPIN CUX2

Interaction Score: 3.25

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
RIFAMPIN AGBL4

Interaction Score: 1.63

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
RIFAMPIN SLCO1B1

Interaction Score: 0.38

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
24420746 22562052 21709081 19374892 12085361

Sources:
PharmGKB
RIFAMPIN NOS2

Interaction Score: 0.31

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22341855

Sources:
PharmGKB
RIFAMPIN GSTP1

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29036176 27281183 25798582

Sources:
PharmGKB
RIFAMPIN CYP2B6

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28389387 27053325 17638512

Sources:
PharmGKB
RIFAMPIN CYP2C8

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15771232

Sources:
NCI
RIFAMPIN CYP1B1

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
6854335

Sources:
NCI
RIFAMPIN NR1I2

Interaction Score: 0.21

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

PMIDs:
17925385 19460945 16480505 21561094 25537531

Sources:
DTC PharmGKB
RIFAMPIN CYP3A5

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26291341 18695978

Sources:
DTC PharmGKB
RIFAMPIN TNF

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22151084

Sources:
PharmGKB
RIFAMPIN CYP2C9

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300 20941486

Sources:
DTC PharmGKB
RIFAMPIN CYP2C19

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC PharmGKB
RIFAMPIN CYP3A4

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300 26291341 24839948

Sources:
DTC PharmGKB
RIFAMPIN ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
RIFAMPIN CYP1A2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
RIFAMPIN CYP2D6

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
RIFAMPIN AR

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

DTC: RIFAMPICIN

Version: 02-September-2020

Alternate Names:

CHEMBL374478 ChEMBL Drug ID

Drug Info:

Publications:

Hennessy EJ et al., 2015, Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity., J Med Chem

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Karthikeyan C et al., 2015, IND-2, a pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinoline derivative, circumvents multi-drug resistance and causes apoptosis in colon cancer cells., Bioorg Med Chem

NCI: RIFAMPIN

Version: 14-September-2017

Alternate Names:

C811 NCI drug code

Drug Info:

Publications:

Prueksaritanont et al., 2005, Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes., Pharm. Res.

Wu et al., 1983, Non-competitive inhibition of hepatic and intestinal aryl hydrocarbon hydroxylase activities from rats by rifampin., J. Nat. Prod.

PharmGKB: rifampin

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Kim SH et al., 2011, NAT2, CYP2C9, CYP2C19, and CYP2E1 genetic polymorphisms in anti-TB drug-induced maculopapular eruption., Eur J Clin Pharmacol

Pan H et al., 2019, Association of FAM65B, AGBL4, and CUX2 genetic polymorphisms with susceptibility to antituberculosis drug-induced hepatotoxicity: validation study in a Chinese Han population., Pharmacogenet Genomics

Dutreix C et al., 2014, Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin., Eur J Clin Pharmacol

TTD: Rifampin
- Version: 2020.06.01
Alternate Names:

D0G3DL TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL374478
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

RIFAMPIN Drug Record

RIFAMPIN chembl:CHEMBL374478 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 30720667

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 24420746 22562052 21709081 19374892 12085361

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22341855

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29036176 27281183 25798582

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28389387 27053325 17638512

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15771232

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 6854335

Sources: NCI

Interaction Types & Directionality: agonist (activating)

Interaction Info:

PMIDs: 17925385 19460945 16480505 21561094 25537531

Sources: DTC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26291341 18695978

Sources: DTC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22151084

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300 20941486

Sources: DTC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300 26291341 24839948

Sources: DTC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Interaction Types & Directionality:

n/a

PMIDs:
30720667

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
24420746 22562052 21709081 19374892 12085361

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22341855

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29036176 27281183 25798582

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28389387 27053325 17638512

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15771232

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
6854335

Sources:
NCI

Interaction Types & Directionality:

agonist (activating)

PMIDs:
17925385 19460945 16480505 21561094 25537531

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26291341 18695978

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22151084

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22931300 20941486

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22931300 26291341 24839948

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

CHEMBL374478 ChEMBL Drug ID

Alternate Names:

C811 NCI drug code

Publications:

Prueksaritanont et al., 2005, Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes., Pharm. Res.

Wu et al., 1983, Non-competitive inhibition of hepatic and intestinal aryl hydrocarbon hydroxylase activities from rats by rifampin., J. Nat. Prod.

Alternate Names:

D0G3DL TTD Drug ID